Publications
Detailed Information
Tacrolimus is an alternative therapeutic option for the treatment of refractory lupus nephritis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, T. | - |
dc.contributor.author | Oh, K-H | - |
dc.contributor.author | Joo, K. W. | - |
dc.contributor.author | Kim, Y. S. | - |
dc.contributor.author | Han, J. S. | - |
dc.contributor.author | Chin, H. J. | - |
dc.contributor.author | Kim, S. | - |
dc.contributor.author | Ahn, C. | - |
dc.date.accessioned | 2012-05-25T08:16:22Z | - |
dc.date.available | 2012-05-25T08:16:22Z | - |
dc.date.issued | 2010-07 | - |
dc.identifier.citation | LUPUS; Vol.19 8; 974-980 | ko_KR |
dc.identifier.issn | 0961-2033 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76492 | - |
dc.description.abstract | We conducted an open-labeled, prospective study to determine the efficacy and safety of tacrolimus as an alternative therapeutic option for those patients with refractory lupus nephritis. The study population comprised one male and eight female patients with diffuse proliferative lupus nephritis. All patients had failed to respond to sufficient intravenous cyclophosphamide therapy with proteinuria of >= 1 g/day and active urinary sediments. Tacrolimus (0.1 mg/kg/day) was administered for 1 year with adjusting drug level (4-10 mg/l). The mean serum creatinine level and spot urine protein creatinine ratio (UPCR) at baseline were 1.39 mg/dl and 2.27, respectively. After the treatment, proteinuria reduced significantly from median UPCR value of 2.19 (range, 1.19-3.34) to 0.44 (range, 0.12-2.13) (p < 0.05). Seven (78%) of the nine patients showed a complete clinical response, which was defined as stabilization in the disease-activity markers and serum creatinine level with reduction of >= 50% in UPCR; two patients showed complete remission with UPCR <0.2. One patient showed treatment failure because of the disease progression. No serious adverse effects were observed during the study. This study demonstrates that tacrolimus can show a significant therapeutic response in cases that are refractory to the standard regimen for diffuse proliferative lupus nephritis. Lupus (2010) 19, 974-980. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | SAGE PUBLICATIONS LTD | ko_KR |
dc.subject | lupus nephritis | ko_KR |
dc.subject | tacrolimus | ko_KR |
dc.subject | proteinuria | ko_KR |
dc.subject | systemic lupus erythematosus | ko_KR |
dc.title | Tacrolimus is an alternative therapeutic option for the treatment of refractory lupus nephritis | ko_KR |
dc.type | Article | ko_KR |
dc.identifier.doi | 10.1177/0961203310366573 | - |
dc.citation.journaltitle | LUPUS | - |
dc.description.citedreference | Li XY, 2009, AM J KIDNEY DIS, V54, P51, DOI 10.1053/j.ajkd.2009.02.018 | - |
dc.description.citedreference | Appel GB, 2009, J AM SOC NEPHROL, V20, P1103, DOI 10.1681/ASN.2008101028 | - |
dc.description.citedreference | Szeto CC, 2008, RHEUMATOLOGY, V47, P1678, DOI 10.1093/rheumatology/ken335 | - |
dc.description.citedreference | Bao H, 2008, J AM SOC NEPHROL, V19, P2001, DOI 10.1681/ASN.2007121272 | - |
dc.description.citedreference | Faul C, 2008, NAT MED, V14, P931, DOI 10.1038/nm.1857 | - |
dc.description.citedreference | Chen YE, 2008, CLIN J AM SOC NEPHRO, V3, P46, DOI 10.2215/CJN.03280807 | - |
dc.description.citedreference | Tse KC, 2007, LUPUS, V16, P46, DOI 10.1177/0961203306073167 | - |
dc.description.citedreference | Mok CC, 2006, SEMIN ARTHRITIS RHEU, V36, P71, DOI 10.1016/j.semarthrit.2006.04.008 | - |
dc.description.citedreference | Westhoff TH, 2006, CLIN NEPHROL, V65, P393 | - |
dc.description.citedreference | Maruyama M, 2006, CLIN NEPHROL, V65, P276 | - |
dc.description.citedreference | MOK CC, 2006, AM J MED, V119, P355 | - |
dc.description.citedreference | Baca V, 2006, LUPUS, V15, P490, DOI 10.1191/0961203306lu2312oa | - |
dc.description.citedreference | Ginzler EM, 2005, NEW ENGL J MED, V353, P2219 | - |
dc.description.citedreference | Mok CC, 2005, KIDNEY INT, V68, P813 | - |
dc.description.citedreference | Davies TH, 2005, BIOCHEMISTRY-US, V44, P2030, DOI 10.1021/bi048503v | - |
dc.description.citedreference | Sidiropoulos PI, 2005, LUPUS, V14, P49 | - |
dc.description.citedreference | Houssiau FA, 2004, ARTHRITIS RHEUM, V50, P3934, DOI 10.1002/art.20666 | - |
dc.description.citedreference | Politt D, 2004, CLIN NEPHROL, V62, P49 | - |
dc.description.citedreference | Flanc RS, 2004, AM J KIDNEY DIS, V43, P197, DOI 10.1053/j.ajkd.2003.10.012 | - |
dc.description.citedreference | Illei GG, 2001, ANN INTERN MED, V135, P248 | - |
dc.description.citedreference | Sadeque AJM, 2000, CLIN PHARMACOL THER, V68, P231, DOI 10.1067/mcp.2000.109156 | - |
dc.description.citedreference | Korbet SM, 2000, AM J KIDNEY DIS, V35, P904 | - |
dc.description.citedreference | Ferrario L, 2000, RHEUMATOLOGY, V39, P218 | - |
dc.description.citedreference | Levey AS, 1999, ANN INTERN MED, V130, P461 | - |
dc.description.citedreference | Mok CC, 1998, ARTHRITIS RHEUM, V41, P831 | - |
dc.description.citedreference | Boumpas DT, 1998, LUPUS, V7, P622 | - |
dc.description.citedreference | Duddridge M, 1997, ANN RHEUM DIS, V56, P690 | - |
dc.description.citedreference | Gourley MF, 1996, ANN INTERN MED, V125, P549 | - |
dc.description.citedreference | SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205 | - |
dc.description.citedreference | BOUMPAS DT, 1993, ANN INTERN MED, V119, P366 | - |
dc.description.citedreference | NING YM, 1993, J BIOL CHEM, V268, P6073 | - |
dc.description.citedreference | BOUMPAS DT, 1992, LANCET, V340, P741 | - |
dc.description.citedreference | OKEEFE SJ, 1992, NATURE, V357, P692 | - |
dc.description.tc | 2 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.